Cilostazol ameliorates nephropathy in type 1 diabetic rats involving improvement in oxidative stress and regulation of TGF-Beta and NF-kappaB

Bioscience, Biotechnology, and Biochemistry
Wen-Chin LeeHuei-Jane Lee

Abstract

Diabetic nephropathy is characterized as the progressive development of renal insufficiency in a setting of hyperglycemia. Previous studies indicate that reactive oxygen species (ROS) play an important role in high glucose-induced renal injury. Cilostazol was reported to lower the production of superoxide significantly in situ. We hypothesized that cilostazol administration in streptozotocin-induced diabetic rats exerts effects via improving oxidative stress. Male Sprague-Dawley rats were fed with cilostazol (5 mg/kg or 25 mg/kg) for 12 weeks after streptozotocin-induced diabetes mellitus. The results showed that cilostazol decreased reactive oxygen species activity significantly in the kidneys of diabetic rats and improved the urine albumin/creatinine ratio. Cilostazol can also improve the levels of serum cholesterol, triglyceride, and LDL-cholesterol. Additionally, diabetes-caused increased glomerular size, TGF-beta, and NF-kappaB decreased under treatment with cilostazol in diabetic rats. Our results indicate that cilostazol has beneficial effects in early diabetic nephropathy.

References

Jan 1, 1991·The Journal of Clinical Investigation·B A WolfJ Turk
Mar 1, 1995·Kidney International·B A YoungK Seidel
Jan 1, 1996·Annual Review of Immunology·A S Baldwin
Aug 5, 1999·Kidney International·G Wolf, F N Ziyadeh
Mar 14, 2000·Current Opinion in Cell Biology·S H Soderling, J A Beavo
Jul 23, 2003·Journal of the American Society of Nephrology : JASN·Hi Bahl LeeHunjoo Ha
Jan 20, 2004·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Anoop MisraAtul Kumar
Jul 29, 2004·American Journal of Physiology. Renal Physiology·Jingfei ChengJoseph P Grande
Jul 29, 2004·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Sergio MezzanoJesús Egido
May 3, 2005·Cardiovascular Diabetology·Jeanette Schultz JohansenAdviye Ergul
May 15, 2007·Nephrology·Greg H Tesch, Terri J Allen
Aug 3, 2007·American Journal of Nephrology·Yi YangJianghua Chen
Feb 18, 2009·Journal of Agricultural and Food Chemistry·Wen-Chin LeeHuei-Jane Lee

❮ Previous
Next ❯

Citations

Oct 19, 2012·Clinical Science·Jun Wada, Hirofumi Makino
Jun 13, 2015·Journal of Diabetes Research·Stephanie Toth-Manikowski, Mohamed G Atta
Jun 1, 2014·Chemico-biological Interactions·Amjid AhadWaseem Ahmad Siddiqui
Mar 17, 2015·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·Maximilian von HeesenMohammed R Moussavian
May 2, 2019·Experimental Biology and Medicine·Cláudia Silva SouzaTelma de Jesus Soares
Dec 7, 2013·Circulation Journal : Official Journal of the Japanese Circulation Society·Tsung-Ming LeeNen-Chung Chang
Dec 18, 2013·Clinical and Experimental Pharmacology & Physiology·Ahmed M TaiyebDuane C Kraemer
Feb 13, 2020·Journal of Clinical Medicine·Javier Donate-CorreaJuan F Navarro-González
Aug 25, 2020·The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology·Chien-Wen ChianHuei-Jane Lee
Dec 23, 2015·Journal of Endocrinological Investigation·X DengM Shen
Mar 16, 2017·Endocrine·Nicole J Asal, Karolina A Wojciak
Feb 8, 2021·Aging·Devin KepchiaPamela Maher
Jun 15, 2021·Frontiers in Cell and Developmental Biology·Yu CaoHaifeng Tang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.